PTD-DBM Research

PTD-DBM is a synthetic peptide designed to block one protein-protein interaction. The experimental research on it is small in volume, preclinical, and concentrated in one laboratory.

What PTD-DBM Is

PTD-DBM is a chimeric peptide with three joined parts. A protein transduction domain of arginine residues carries cargo across cell membranes. A short flexible linker follows. The third part is the Dishevelled-binding motif, copied from the human protein CXXC5.

It is not a natural peptide, and no parent hormone's evidence transfers to it. Its CAS registry number, 1609454-11-6, traces to supplier catalog depositions rather than to a primary publication. The registered structure also differs from the construct used in the published experiments, which carried an extra terminal residue and a fluorescent visualization tag ^[1].

How PTD-DBM Is Reported to Work

CXXC5 negatively regulates the Wnt/beta-catenin signaling pathway. It binds Dishevelled, an intracellular signaling protein, and damps the pathway down. PTD-DBM is designed to compete for that binding site. Blocking that regulator is intended to raise Wnt/beta-catenin activity indirectly.

In human dermal fibroblasts in vitro, the peptide raised beta-catenin, alpha-smooth muscle actin and collagen I in a concentration-dependent way, and raised endothelin-1 as well ^[1]. Silencing beta-catenin with siRNA abolished the peptide's effect on alpha-smooth muscle actin and collagen I in that same in vitro system. That is a result in cultured cells. It is not evidence of an outcome in an animal or a person.

Preclinical Wound-Healing Research

PTD-DBM was built as a wound-healing tool, not as a hair compound. In the mouse study that introduced it, the peptide was applied alone, applied with valproic acid, and set against epidermal growth factor as an active comparator ^[1]. That paper calls epidermal growth factor a currently prescribed wound-healing agent. That arm is the only head-to-head against a growth-factor control anywhere in the peptide's record. In those mice the peptide alone accelerated wound healing as efficiently as epidermal growth factor ^[1]. That is a mouse result in wounds, not in hair. The reported in vivo headline of that paper is a combination result. Co-treatment of mouse skin wounds with the peptide and valproic acid synergistically accelerated wound healing, much more efficiently than epidermal growth factor alone ^[1]. Valproic acid is a separate GSK-3beta inhibitor that reaches the same pathway by another route.

Treatment in that experiment ran for eleven days, in seven-week-old male C3H mice. Wound closure was measured in 16 mice per group, with 5 per group for histology and the collagen assay. A 2023 mouse study from the same group delivered the peptide, valproic acid, or both from a hydrogel patch and reported reduced scarring, again in wounds rather than hair ^[5].

Preclinical Hair Research

The central hair paper, published in 2017, reported several distinct findings ^[2]. CXXC5 was elevated in miniaturized hair follicles and arrector pili muscles in human balding scalp tissue. That is an observation in human tissue, not a test of the peptide in people. CXXC5-knockout mice showed accelerated hair regrowth. That is a genetic result about the target protein, not a peptide result. Valproic acid further increased regrowth in those knockout mice, again without the peptide. Separately, disrupting the CXXC5-Dishevelled interaction with the competitor peptide activated Wnt/beta-catenin signaling and accelerated hair regrowth and wound-induced hair follicle neogenesis in mice.

That paper is paywalled, and its abstract does not report group sizes. An independent 2026 review describes the same experiment ^[6]. The comparison in which the peptide outperformed minoxidil was peptide plus valproic acid, tested against minoxidil alone ^[6]. In that mouse comparison valproic acid was present at roughly 250 times the concentration of the peptide ^[6]. A combination result is not evidence about the peptide by itself. Valproic acid also has its own separate human hair-loss data, which does not transfer to this peptide.

A 2023 mouse and cell-culture study is the clearest evidence of the peptide acting alone on hair ^[3]. Without valproic acid, it restored mouse hair regrowth and wound-induced neogenesis that prostaglandin D2 had suppressed. It also rescued vibrissa (whisker follicle) elongation ex vivo and beta-catenin in keratinocytes in vitro. That is a rescue design. It shows the peptide undoing an imposed insult, not growing hair in an untreated animal.

The same 2023 paper also tested a dihydrotestosterone model. There the small molecule KY19382 completely restored beta-catenin suppression, and only KY19382 completely improved vibrissa elongation ^[3]. Against dihydrotestosterone the peptide was incomplete where the small molecule was complete. Those readouts were molecular and ex vivo. That paper ran no in vivo arm comparing the peptide against dihydrotestosterone.

KY19382 is a different molecule, developed by the same laboratory. It inhibits both the CXXC5-Dishevelled interaction and GSK-3beta, where the peptide addresses only the first ^[3]. In 2021 the originating group wrote that the peptide is limited for routine application on cost and stability grounds, and selected KY19382 instead ^[4]. The same laboratory nonetheless kept running peptide experiments through 2023 ^[3][5].

Human Research and Regulatory Status

No research in people was located for PTD-DBM. The human material in its record is cultured cells and stained balding scalp tissue, not treated volunteers ^[1][2]. A ClinicalTrials.gov search returns zero studies for PTD-DBM and zero for KY19382, for any indication. The peptide has been in the literature since 2015 and has not reached a trial in that registry. It holds no FDA approval, and no FDA application of any kind was located for it.

CK Regeon, founded by the senior author of the primary papers, registered NCT05833906 ^[11]. That Phase 1 transdermal study in 52 healthy male subjects completed in January 2024. Its stated purpose is skin regeneration and wounds, not hair loss. The registry does not disclose which molecule the agent CKR-051 is, so the record does not place this peptide in human testing. No results have been posted more than two and a half years after completion. An unposted Phase 1 is not evidence in either direction.

One peer-reviewed review abstract states that investigations demonstrate clinical efficacy of peptides such as PTD-DBM ^[7]. That claim is contradicted by the body and comparison table of the same review, which describe rodent work and no official approval. The same review also calls the 2017 experiments mouse models of androgenetic alopecia ^[7]. Those experiments were depilation-induced hair regrowth and wound-induced neogenesis in C3H mice ^[2].

Safety Data

One published safety look at the peptide was located. It is very small. In the 2015 mouse study, wounds were treated for eleven days and then examined six months after wounding for two oncogenic markers, c-Myc and cyclin D1 ^[1]. Neither marker rose, and no abnormal skin phenotype was reported. The same two markers were also unchanged in the cultured fibroblasts ^[1]. That follow-up used 3 mice per group and stained wound skin only. It reports no pharmacokinetics, no systemic exposure, no hematology and no organ histology.

Beyond that, no dedicated toxicology study, dose-ranging work or repeat-dose toxicity study of the peptide was located. The arginine-rich transduction domain is non-selective by design and will enter cells other than the intended ones. An independent dermatology review names a liability for this class of Wnt modulators ^[7]. It lists aberrant pathway activation associated with colorectal and hepatocellular carcinoma, and a narrow therapeutic window. Those limitations are attached in that source to a three-item class including PTD-DBM, not to the peptide alone. The originating group offers a counter-argument. It holds that activating the pathway indirectly through a negative regulator may reduce that risk ^[1]. The origin paper's first author restates that argument in a 2025 single-author review ^[8]. That review declares no conflicts of interest and carries no company affiliation. Both positions are arguments rather than settled data.

Independence, Replication and Conflicts of Interest

A screen of all 51 papers citing the 2017 hair study, plus a full-text search for the peptide's name, found no independent group using it. In that set, every experimental use of PTD-DBM in a cell or an animal comes from one Yonsei University laboratory or its spin-out companies. No independent replication of the hair finding, or of any other PTD-DBM finding, was located.

The conflict of interest is disclosed and direct. Kang-Yell Choi is senior author on the primary papers and is CEO of CK Regeon, which licenses the pathway activator disclosed in that work ^[3]. Corporate affiliations appear in the author address blocks across the series. Two other groups appear in this literature working on the CXXC5-Dishevelled target, and neither used this peptide. One used the small molecule KY19382 in diabetic mouse wounds ^[9]. The other used a DNA aptamer in human dermal papilla cells in vitro, and is commercially interested in that aptamer ^[10]. Both support the target concept, and neither is a replication.

No retraction, correction or expression of concern was located on any PTD-DBM paper.

Conclusion

PTD-DBM has a coherent mechanism and a thin evidence base. Its published record is cultured cells, stained human scalp tissue, and mouse wound and hair experiments, all preclinical. In mouse wounds the peptide alone accelerated healing as efficiently as an active growth-factor comparator. The clearest peptide-alone hair result in mice is a rescue design. The hair comparison against minoxidil is a combination result with valproic acid. The experimental literature is single-laboratory, commercially conflicted and unreplicated. ClinicalTrials.gov lists no human trial of the peptide.

Frequently Asked Questions

Has PTD-DBM been studied in humans?

No research in people was located for PTD-DBM, and a ClinicalTrials.gov search returns no trial of it, for any indication. The human material in its record is cultured cells and stained balding scalp tissue, not treated volunteers ^[1][2].

Is KY19382 the same compound as PTD-DBM?

No. KY19382 is a small molecule inhibiting both the CXXC5-Dishevelled interaction and GSK-3beta, where the peptide addresses only the first ^[3]. In a dihydrotestosterone model the small molecule completely restored beta-catenin, and it alone completely improved vibrissa elongation, where the peptide was incomplete ^[3]. Those readouts were molecular and ex vivo.

Does the published hair effect require valproic acid?

Not entirely. The peptide alone restored suppressed hair regrowth and neogenesis in mice in a 2023 rescue study ^[3]. The comparison against minoxidil, however, was a peptide plus valproic acid combination ^[6]. That combination result is not evidence about the peptide alone.

References

1. 1

   Lee SH, Kim MY, Kim HY, et al. The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing. J Exp Med. 2015;212(7):1061-1080. PMID 26056233. DOI: 10.1084/jem.20141601
2. 2

   Lee SH, Seo SH, Lee DH, Pi LQ, Lee WS, Choi KY. Targeting of CXXC5 by a competing peptide stimulates hair regrowth and wound-induced hair neogenesis. J Invest Dermatol. 2017;137(11):2260-2269. PMID 28595998. DOI: 10.1016/j.jid.2017.04.038
3. 3

   Ryu YC, et al. CXXC5 mediates DHT-induced androgenetic alopecia via PGD2. Cells. 2023;12(4). PMID 36831222. DOI: 10.3390/cells12040555
4. 4

   Ryu YC, et al. KY19382, a novel activator of Wnt/beta-catenin signalling, promotes hair regrowth and hair follicle neogenesis. Br J Pharmacol. 2021;178(12):2533-2546. PMID 33751552. DOI: 10.1111/bph.15438
5. 5

   Lee SH, et al. Adhesive hydrogel patch-mediated combination drug therapy induces regenerative wound healing through reconstruction of regenerative microenvironment. Adv Healthc Mater. 2023;12(18):e2203094. PMID 36854308. DOI: 10.1002/adhm.202203094
6. 6

   Fan C, et al. Overview of short peptides for hair loss. Biomedicines. 2026;14(4). PMID 42072405
7. 7

   Mehta A, et al. Revolutionary approaches to hair regrowth: follicle neogenesis, Wnt/beta-catenin signaling, and emerging therapies. Cells. 2025;14(11). PMID 40497955
8. 8

   Lee SH. Molecular signaling pathways in wound-induced hair-follicle neogenesis. Cells. 2025;14(6). PMID 40136689
9. 9

   Chen Y, et al. CXXC5 function blockade promotes diabetic wound healing through stimulating fibroblast and vascular endothelial cell activation. Cell Commun Signal. 2025;23(1):108. PMID 40001144
10. 10

    Won A, et al. Effect of DNA aptamer through blocking of negative regulation of Wnt/beta-catenin signaling in human hair follicle dermal papilla cells. Skin Res Technol. 2023;29(5):e13326. PMID 37231925
11. 11

    ClinicalTrials.gov. NCT05833906. Safety, tolerability, and pharmacokinetic evaluations of CKR-051 after transdermal administration in healthy male subjects. Completed 2024-01-08.